Company Profile
Relmada Stock Price, News & Catalysts
- Ticker:
- RLMD
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
4.72 USD (+5.59%)
Close
Last updated: August 12, 2026
673M USD
Market cap
Why the stock is moving
As of Aug 12, 2026, RLMD closed up 5.59% at $4.72. No new same-company headline was identified in the current news window.
Company overview
Bladder Cancer Drug-Device Company
Relmada Therapeutics develops NDV-01 for localized treatment of non-muscle invasive bladder cancer.
NDV-01
The system delivers gemcitabine locally and continuously within the bladder, seeking durable exposure while limiting systemic toxicity.
RESCUE Program
The Phase 3 RESCUE program will evaluate NDV-01 in second-line BCG-unresponsive disease and adjuvant intermediate-risk NMIBC.
Future catalysts
- Initiation of the Phase 3 RESCUE registrational program is targeted for mid-2026.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Relmada (RLMD)?
Relmada (RLMD) most recently closed at 4.72 USD, a +5.59% move versus the previous session.
What is the market cap of Relmada (RLMD)?
Relmada currently has a market capitalization of 673M USD on BioPharmSignal.
What does Relmada do?
Bladder Cancer Drug-Device Company Relmada Therapeutics develops NDV-01 for localized treatment of non-muscle invasive bladder cancer. NDV-01 The system delivers gemcitabine locally and continuously within the bladder, seeking durable exposure while limiting systemic toxicity. RESCUE Program The Phase 3 RESCUE program will evaluate NDV-01 in second-line...
On which exchange is RLMD stock listed?
Relmada (RLMD) is associated with NASDAQ, United States, Biopharma.
What is NDV-01?
Bladder Cancer Drug-Device Company Relmada Therapeutics develops NDV-01 for localized treatment of non-muscle invasive bladder cancer.
Which conditions is Relmada targeting with NDV-01?
Relmada is associated with cancer therapeutics based on its company overview and current catalyst commentary.
How does Relmada describe recent progress with NDV-01?
Initiation of the Phase 3 RESCUE registrational program is targeted for mid-2026.
What is Bladder?
Bladder Cancer Drug-Device Company Relmada Therapeutics develops NDV-01 for localized treatment of non-muscle invasive bladder cancer.